Renalaid-A

Renalaid-A is the acid (part A) concentrate of a two-part bicarbonate hemodialysis solution system. It is not a medicine taken by patients directly; rather, it is a concentrated dialysate component that dialysis staff mix with the bicarbonate (part B) concentrate and purified water, in the exact proportions specified by the dialysis machine manufacturer, to prepare the final dialysate used during hemodialysis.

Established use

• Preparation of dialysate for maintenance and acute hemodialysis in patients with end-stage renal disease (ESRD) or acute kidney injury requiring renal replacement therapy, when used strictly with a compatible bicarbonate-based hemodialysis delivery system.

Renalaid-A must always be used together with the corresponding bicarbonate component and purified water as a complete, validated three-part (or proportioning-system-defined) dialysate system — it is never used alone and has no independent therapeutic indication outside this combination.

Each liter of Acidic component [HCO3 Hemodialysis Solution] concentrate typically contains:

Exact concentrations vary slightly by manufacturer/formulation; the label of the specific product package must always be checked before use. Some formulations may also include a small amount of dextrose. This concentrate is highly hypertonic and is never administered undiluted.

Renalaid-A is a sterile, pyrogen-free, concentrated electrolyte and acid solution manufactured for use exclusively as one component of a bicarbonate hemodialysis system. During dialysis treatment, it is drawn by the dialysis machine's proportioning pumps and automatically diluted with purified water and mixed with the bicarbonate concentrate to create the final, physiologically balanced dialysate that flows across the dialyzer membrane, allowing removal of uremic toxins and correction of fluid, electrolyte, and acid-base abnormalities in patients with kidney failure.

It is supplied in bulk containers, jugs, or bags intended for connection to certified hemodialysis delivery systems and is used only in supervised dialysis facilities by trained personnel.

Dialysis solution — acid concentrate component used in bicarbonate hemodialysis systems (companion to the corresponding bicarbonate concentrate); Renalaid-A belongs to this class.

Acidic component [HCO3 Hemodialysis Solution] supplies the electrolytes and acid needed to balance the alkaline bicarbonate component and to buffer against precipitation of calcium and magnesium carbonate salts when the two concentrates are mixed with water.

• Sodium chloride maintains plasma osmolality and helps regulate fluid balance and blood pressure during dialysis.
• Potassium chloride is included at a controlled concentration to support normal cardiac and skeletal muscle electrical activity and to help correct dialysis-related potassium shifts.
• Calcium chloride maintains ionized calcium levels important for neuromuscular function, cardiac contractility, and coagulation.
• Magnesium chloride supports normal enzymatic reactions and neuromuscular transmission.
• Acetic acid lowers the pH of the concentrate so that, on dilution and mixing with the bicarbonate component, the final dialysate reaches a physiologic pH and prevents carbonate precipitation; a small amount of acetate is also metabolized to bicarbonate in the body, contributing modestly to buffering.

When properly diluted and combined with the bicarbonate component, the resulting dialysate diffuses electrolytes and buffer across the dialyzer membrane along concentration gradients, correcting the metabolic acidosis, electrolyte derangements, and fluid overload typical of kidney failure.

Renalaid-A is connected directly to the acid-concentrate port of the hemodialysis machine using the manufacturer-specified connector. The machine automatically proportions and mixes it with purified water and the bicarbonate concentrate to generate the final dialysate in real time; it is not injected, infused, or given by any other manual route. Container integrity (intact seal, no particulate matter, correct labeling, and expiry date) must be verified before connection, and conductivity/pH of the final dialysate should be verified per facility protocol before starting each session.

Renalaid-A is not a systemically administered drug in the conventional sense, so classical drug-drug interaction studies do not apply. However, clinically important interactions with the dialysis process itself should be noted:

• Mismatched or incompatible bicarbonate component: using Renalaid-A with a bicarbonate concentrate or dialysis system it was not formulated/validated for can cause incorrect final electrolyte or buffer concentrations, precipitation, or dangerous acid-base shifts.
• Concurrent medications affecting electrolytes: patients taking potassium-sparing diuretics, ACE inhibitors/ARBs, calcium or magnesium-containing supplements/antacids, or digoxin may be more sensitive to the electrolyte shifts produced during dialysis with this solution; serum levels should be monitored per the treating physician's guidance.
• Citrate or other anticoagulants used during dialysis: regional citrate anticoagulation can alter ionized calcium balance and should be coordinated with the electrolyte content of the dialysate.

Adverse effects associated with Renalaid-A generally arise from incorrect dilution/mixing or from the dialysis process itself rather than from the concentrate when used correctly:

• Fluid and electrolyte imbalance (hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, hypernatremia)
• Hypovolemia and intradialytic hypotension
• Muscle cramps
• Nausea, vomiting, or malaise related to rapid fluid/electrolyte shifts
• Metabolic acidosis or alkalosis if mixed incorrectly
• Rarely, hypersensitivity-type reactions to a component

Most of these effects are preventable with correct preparation and are managed by adjusting the dialysis prescription; report any unusual symptoms during dialysis to the dialysis team immediately.

There are no dedicated reproductive studies of Renalaid-A itself, since it is a dialysate component rather than a systemically dosed drug. Hemodialysis itself is used in pregnant and lactating patients with kidney failure when clinically necessary, under close obstetric and nephrology supervision, with adjustments to dialysis frequency/duration and dialysate composition as needed. Renalaid-A should be used in pregnant or breastfeeding patients only as part of a dialysis prescription individualized and supervised by the treating physician, with careful attention to electrolyte and fluid targets; there is no evidence that correctly prepared and administered Renalaid-A poses direct fetal or infant risk beyond that inherent to dialysis itself.

Renalaid-A must be prepared, mixed, and administered strictly according to the dialysis machine manufacturer's protocol and only by trained dialysis personnel in a supervised hemodialysis facility.

• Never use Renalaid-A undiluted or in an incorrect mixing ratio; incorrect concentration can cause dangerous electrolyte disturbances or metabolic acidosis/alkalosis, which can be life-threatening.
• Use only with the specific bicarbonate component and dialysis machine/proportioning system for which it has been validated (see Contraindications).
• Verify container integrity before use — do not use if the seal is broken, if the solution is discolored, or if visible particulate matter is present; discard unused/opened concentrate per facility protocol.
• Confirm conductivity and pH of the final mixed dialysate before and during each dialysis session per facility protocol.
• Monitor serum electrolytes (sodium, potassium, calcium, magnesium) and acid-base status regularly during and between dialysis sessions.
• Not intended for any use outside the supervised hemodialysis setting; not for injection, oral, or any route other than machine-proportioned dialysate preparation.
• Keep out of reach of children; if accidentally ingested, seek immediate medical attention or contact a poison control center.

"Overdose" in the context of Renalaid-A generally refers to accidental undiluted exposure, incorrect mixing ratio, or excessive dialysate exposure during a session, which can cause severe electrolyte disturbances (dangerous hyperkalemia, hypercalcemia, or hypernatremia), severe metabolic acidosis or alkalosis, cardiac arrhythmia, or hemodynamic instability. If accidental ingestion, incorrect mixing, or a suspected dosing error occurs, stop use immediately and seek emergency medical attention or contact a poison control center right away; within a dialysis session, any suspected error must be reported to and managed by the dialysis care team immediately, with prompt correction of the dialysate and supportive treatment of any resulting electrolyte or acid-base abnormality.

Store at room temperature (below 30°C), away from direct sunlight and moisture. Keep container sealed until use and keep out of reach of children. Do not use if the seal is broken or damaged.

Pediatric use: Renalaid-A may be used to prepare dialysate for pediatric hemodialysis patients using dialysis machines and prescriptions validated for pediatric use; volumes, flow rates, and electrolyte targets must be individualized by a pediatric nephrologist, as safety and dosing in children depend entirely on the specific pediatric dialysis protocol used.

Elderly patients: No specific dose adjustment of Renalaid-A itself is required for elderly patients, but this population is more prone to cardiovascular instability and electrolyte shifts during dialysis, so closer intradialytic monitoring is advised.

Renal impairment: Renalaid-A is used specifically because the patient has renal failure requiring dialysis; the dialysate composition and dialysis prescription are individualized to the patient's residual renal function and electrolyte status.

Hepatic impairment: No specific adjustment of Renalaid-A is established for hepatic impairment; the treating physician may adjust the overall dialysis prescription based on the patient's fluid and electrolyte status.

Renalaid-A is used for the duration of each hemodialysis session (typically 3-5 hours), repeated as part of the patient's ongoing maintenance hemodialysis schedule (commonly 3 sessions per week) for as long as renal replacement therapy is required, as determined by the treating nephrologist.

Dialysis solutions / Renal replacement therapy concentrates (acid component of bicarbonate hemodialysis systems)

Acidic component [HCO3 Hemodialysis Solution] works by supplying, in concentrated form, the electrolytes (sodium, potassium, calcium, magnesium) and acid (acetic acid) needed to formulate physiologic dialysate. When diluted with purified water and combined with the bicarbonate component by the dialysis machine, the acetic acid lowers the pH just enough to prevent calcium and magnesium carbonate from precipitating out of solution, while the electrolytes establish concentration gradients across the dialyzer membrane. During hemodialysis, blood is passed across one side of a semipermeable dialyzer membrane while this dialysate flows on the other side; solutes and buffer move by diffusion (and ultrafiltration removes excess fluid), correcting uremic toxin accumulation, electrolyte imbalance, and metabolic acidosis in patients with kidney failure.

Renalaid-A can be used to prepare dialysate for pediatric patients undergoing hemodialysis, but only with dialysis machines, proportioning systems, and dialysis prescriptions specifically validated for pediatric use. Safety and dosing are not established as a fixed regimen for children in the way an oral or injectable drug would be; instead, the pediatric nephrology team individualizes the dialysate composition, blood/dialysate flow rates, and session duration based on the child's age, weight, and clinical status. Renalaid-A should never be used in a pediatric setting outside a properly validated pediatric hemodialysis protocol.